Physician profile
Michael A Hood
NPI 1124134952
$1,744.14
in general payments reported to CMS, 2019-2025
21 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $285 · 2021: $162 · 2022: $147 · 2023: $252 · 2024: $153 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $668.24 | 2019-2025 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $173.73 | 2022-2023 | Seglentis |
| Ferring Pharmaceuticals INC. | $166.27 | 2019-2022 | |
| Pacira Therapeutics, INC. | $130.16 | 2019-2020 | |
| Biotissue Holdings INC. | $102.78 | 2024 | |
| Bioventus LLC | $65.93 | 2019-2024 | Exogen Ultrasound Bone Healing System |
| Pacira Pharmaceuticals Incorporated | $59.71 | 2019-2025 | Exparel |
| Depuy Synthes Sales INC. | $43.34 | 2020-2025 | Orthovisc |
| Kci USA, INC. | $38.92 | 2019-2020 | |
| Convatec INC. | $35.39 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $33.04 | 2021 | |
| Zyla Life Sciences, INC. | $32.86 | 2019-2020 | |
| Pfizer INC. | $31.08 | 2019 | |
| Smith+Nephew, INC. | $27.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.07 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $26.14 | 2019 | |
| Merck Sharp & Dohme LLC | $21.50 | 2022 | |
| Orthofix Medical, INC. | $19.82 | 2019 | |
| Allergan, INC. | $14.43 | 2019 | |
| Astellas Pharma Global Development | $13.93 | 2025 | Izervay |
| Janssen Pharmaceuticals, INC | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.